Boswellic acids (K‐Vie™) improves clinical cognitive scores and reduces systemic inflammation in patients with mild to moderate Alzheimer’s disease.

Alzheimer’s disease (AD) remains an incurable neurodegenerative disorder. Neuroinflammation has been now recognized as an important player in the pathogenesis of AD. We conducted a clinical trial to measure whether boswellic acids (K‐Vie™, an enriched Boswellia extract) can improve cognitive and neuropsychiatric symptoms while reducing inflammation in patients with AD.